NAUT vs NBP

Nautilus Biotechnology, Inc. vs NovaBridge Biosciences — Valuation Comparison 2026

NAUT

Biotechnology
Nautilus Biotechnology, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$2.60
Last close
Models
7/13
Active
VS

NBP

Biotechnology
NovaBridge Biosciences
Quality
3.0
out of 10
Value Trap
12
SAFE
Price
$1.87
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NAUT Fair ValueNAUT Upside NBP Fair ValueNBP Upside
Bayesian DCF Intrinsic $0.67 -74.3% $0.37 -80.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.86 -67.0% $1.00 -46.5%
PWERM Option-Based $2.54 -2.2% $2.15 +14.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAUT vs NBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAUT vs NBP — Which Stock Is More Undervalued?

NAUT scores higher with a 4.3/10 quality rating vs NBP's 3.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nautilus Biotechnology, Inc. (NAUT) and NovaBridge Biosciences (NBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAUT currently trades at $2.60 with a QOC of 4.3/10, while NBP trades at $1.87 with a QOC of 3.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).